To Evaluate the Effect of Ginkgo Biloba Extract on Optic Nerve Head Perfusion Examined Using OCTA
- Conditions
- Glaucoma
- Registration Number
- NCT04846179
- Lead Sponsor
- Nova Scotia Health Authority
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria:<br><br> - 18 years of age or older<br><br> - Early open angle glaucoma based on gonioscopy, clinical assessment of optic nerve<br> head, OCT optic nerve and Humphrey Visual Field 24-2 (MD < -10dB) and positive<br> Glaucoma Hemifield Test<br><br> - BCVA equal or better than 6/12<br><br> - Written consent<br><br> - Ability to comply with treatment intervention for duration of study<br><br>Exclusion Criteria:<br><br> - Younger than 18 years of age<br><br> - Angle closure glaucoma or secondary open angle glaucoma<br><br> - Refraction exceeding 6D spherical equivalent or 3D astigmatism<br><br> - Severe corneal, lens, vitreous media opacity limit signal strength of OCTA imaging<br><br> - Severe open angle glaucoma with visual field mean deviation worse than -10dB<br><br> - Inability to comply to treatment intervention (e.g. swallowing difficulty)<br><br> - History of ocular disease affecting ocular perfusion (e.g. CRAO, CRVO, diabetic<br> retinopathy, ocular ischemic syndrome, ischemic optic neuropathy)<br><br> - History of glaucoma surgery<br><br> - Those taking anticoagulant therapy<br><br> - Those with blood disorders or diabetes<br><br> - Women who were pregnant, planning to become pregnant, or who were breast-feeding,<br><br> - Patients with a history of seizures or who were currently taking anti-convulsant<br> medication, and<br><br> - Taking any drugs that may interact with GBE
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Optic nerve head and macula perfusion
- Secondary Outcome Measures
Name Time Method